2020 American Transplant Congress
Assessment of Rapid Optimized Flow Cytometric Crossmatch (FCXM) Assay with Luminex Class I Single Antibody Test
*Purpose: Flow cytometric crossmatch test (FCXM) is critical to detect donor-specific antibodies (DSA) in transplant patients. Rapid, simple and sensitive FCXM procedure can improve HLA…2020 American Transplant Congress
Can HLA-DQ Molecular Mismatch Analysis Be Used to Predict Generation of De Novo Donor-Specific Antibody at an Individual Patient Level?
1Northwestern University, Chicago, IL, 2SUNY Upstate Medical University, Syracuse, NY
*Purpose: De novo donor-specific antibodies (dnDSA), especially to HLA-DQ, are one of the leading causes of late kidney graft failure. Many investigators have attempted to…2020 American Transplant Congress
The Association between Alloimmunity and De Novo Glomerulonephritis Post Kidney Transplantation
Columbia University Medical Center, New York, NY
*Purpose: In contrast to recurrent immune complex-mediated glomerulonephritis (ICGN), de novo ICGN of the allograft is poorly characterized. We hypothesize that alloimmunity results in immune-complex…2020 American Transplant Congress
Clinical Significance of T Cell and B Cell Epitope Prediction as a Risk Factor of De Novo DSA Production after Kidney Transplantation
*Purpose: Chronic antibody-mediated rejection caused by de novo DSA (dnDSA) is a major cause of graft failure. Risk prediction of dnDSA would be important for…2020 American Transplant Congress
A Multicenter Analysis of the Proportion and Pattern of Unexplained HLA Antibodies in Kidney Recipients without a History of Sensitization
*Purpose: Previous studies report a high prevalence of unexplained antibody reactivities on the single antigen bead (SAB) test. In a contemporary multicenter cohort of non-sensitized…2020 American Transplant Congress
Donor-Specific Antibody Test as a Screening Tool for Stable Long-Term Kidney Transplant Recipients
1Department of Nephrology, Madison, WI, 2Department of Surgery, Madison, WI
*Purpose: Donor-specific antibody (DSA) is an established biomarker predicting antibody mediated rejection (AMR), but at substantial cost. The utility of DSA test as a screening…2020 American Transplant Congress
Crosstalk between TLR4 and HLA Class I Mediates P-Selectin Expression and Monocyte Capture to Endothelial Cells
Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA
*Purpose: Transplant recipients developing donor specific HLA antibodies (DSA) are at risk for acute and chronic antibody-mediated rejection (AMR). DSA contribute to the process of…2020 American Transplant Congress
Effects of Donor Specific Antibodies in Intestinal/Multivisceral Transplant Recipients
1University Health System, San Antonio, TX, 2Nebraska Medicine, Omaha, NE
*Purpose: Evaluate the effects of donor specific antibodies (DSAs) on outcomes in post-intestinal/multivisceral (MV) transplant patients and describe the presentation of DSAs post-transplant.*Methods: This single-center…2020 American Transplant Congress
Is the Epitope Mismatch Load Enough to Identify HLA-DQ Mismatches with a Low Risk for De Novo DSA Development?
*Purpose: The development of de novo donor-specific anti-HLA antibodies (dnDSA) remains a major risk factor for poor long-term kidney allograft outcomes. In particular, anti-HLA-DQ dnDSAs,…2020 American Transplant Congress
Association between Longer Hospitalization and Development of De Novo Donor Specific Antibody in Simultaneous Liver-Kidney Transplant Recipients
*Purpose: De novo Donor Specific Antibodies (DSA) are considered a risk factor for worsening kidney allograft outcomes in recipients after simultaneous liver-kidney transplantation (SLK). No…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 47
- Next Page »